Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 19, 2021 / 02:55PM GMT
Release Date Price: $35.36 (-4.10%)
Luca Issi
RBC Capital Markets, Research Division - Research Analyst

Well, great. Hello, everybody, and thank you for dialing in. My name is Luca Issi. I'm a senior biotech analyst here at RBC Capital Markets. And today is our great privilege to have Beth Hougen, the CFO of Ionis for a fireside chat. Thanks so much for joining us. How are you doing today?

Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Great. Thanks for having this, Luca. I appreciate it.

Questions & Answers

Luca Issi
RBC Capital Markets, Research Division - Research Analyst

That's fantastic. So can you maybe start with a question on Akcea. You obviously recently completed the acquisition of Akcea. Can you remind us the rationale behind that decision? And maybe just give us a quick update on the process? And how should we think about cost synergies going forward here?

Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Sure.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot